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Abstract
Background: It has been postulated that ionizing radiation induces breast cancers among atomic bomb (A-bomb)
survivors. We have reported a higher incidence of HER2 and C-MYC oncogene amplification in breast cancers from
A-bomb survivors. The purpose of this study was to clarify the effect of A-bomb radiation exposure on genomic
instability (GIN), which is an important hallmark of carcinogenesis, in archival formalin-fixed paraffin-embedded
(FFPE) tissues of breast cancer by using microarray-comparative genomic hybridization (aCGH).
Methods: Tumor DNA was extracted from FFPE tissues of invasive ductal cancers from 15 survivors who were
exposed at 1.5 km or less from the hypocenter and 13 calendar year-matched non-exposed patients followed by
aCGH analysis using a high-density oligonucleotide microarray. The total length of copy number aberrations (CNA)
was used as an indicator of GIN, and correlation with clinicopathological factors were statistically tested.
Results: The mean of the derivative log ratio spread (DLRSpread), which estimates the noise by calculating the
spread of log ratio differences between consecutive probes for all chromosomes, was 0.54 (range, 0.26 to 1.05). The
concordance of results between aCGH and fluorescence in situ hybridization (FISH) for HER2 gene amplification
was 88%. The incidence of HER2 amplification and histological grade was significantly higher in the A-bomb
survivors than control group (P = 0.04, respectively). The total length of CNA tended to be larger in the A-bomb
survivors (P = 0.15). Correlation analysis of CNA and clinicopathological factors revealed that DLRSpread was
negatively correlated with that significantly (P = 0.034, r = -0.40). Multivariate analysis with covariance revealed that
the exposure to A-bomb was a significant (P = 0.005) independent factor which was associated with larger total
length of CNA of breast cancers.
Conclusions: Thus, archival FFPE tissues from A-bomb survivors are useful for genome-wide aCGH analysis. Our
results suggested that A-bomb radiation may affect the increased amount of CNA as a hallmark of GIN and,
subsequently, be associated with a higher histologic grade in breast cancer found in A-bomb survivors.
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Background
Genomic instability (GIN) is an important hallmark of
an enhanced carcinogenic process in human. Although
there are various forms of GIN, many cancer cells show
higher rates of chromosomal instability, which means
changes in chromosome structure and number, com-
pared with normal cells [1]. Recent cytogenetic analysis
revealed that there were equal numbers of cytogenetic
aberrations in solid cancers and hematological malig-
nancies [2]. Several previous studies have reported the
association between chromosome instability and GIN/
clinical phenotypes in breast cancers. Fridlyand et al. [3]
categorized three breast tumor subtypes based on copy
number aberrations (CNA) in tumor DNA, which
includes DNA copy number gains and losses, and
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any medium, provided the original work is properly cited.suggested that these aberrations were related to shorter
telomeres and the deregulation of the retinoblastoma
(RB) gene pathway using an analysis of array compara-
tive genomic hybridization (aCGH). Andre et al. [4]
divided 106 breast cancers into three subtypes by the
clustering method with the aCGH data and observed a
correlation between cytogenetic subtypes and clinico-
pathologic characteristics, histological grade and intrin-
sic subtypes [5]. Hu et al. [6] and Melchor et al. [7]
classified breast cancers by immunohistochemical stain-
ing pattern and found that triple-negative or basal-like
subtype, which had the highest GIN among these sub-
types, had the highest overall frequencies of CNA. Loo
et al. [8] showed a correlation between fractional allelic
loss and tumor size, mitotic rate and DNA content.
Atomic bomb (A-bomb) survivors who were exposed
at young ages have already reached cancer-prone age.
An increased risk of cancer has continued for decades,
and the incidence of certain types of cancer is still
higher in A-bomb survivors than in control populations
[9-14]. It has been postulated that ionizing radiation
induces breast cancers among A-bomb survivors. Our
recent study demonstrated an association of HER2 and
C-MYC oncogene amplification in breast cancers among
A-bomb survivors with radiation exposure [15]. Onco-
gene amplification is thought to be associated with GIN
and a main characteristic of solid tumors [16]. It is con-
ceivable that radiation from the A-bomb 65 years ago
may have induced a higher level of GIN in A-bomb sur-
vivors as a long-lasting health effect which is associated
with the development of oncogene amplifications and
subsequent carcinogenesis. However, the crucial
mechanisms that can account for a radiation effect indu-
cing GIN on the whole genome of breast cancers in A-
bomb survivors remains elusive.
The rapid progress of technological innovation in bio-
medical science has enabled CGH analysis to be per-
formed with higher resolution using high density
oligonucleotide microarrays [17]. However, utilizing for-
malin-fixed paraffin-embedded (FFPE) archival tissue for
the aCGH, which is the most common form of tissue
preservation in routine practice, remains challenging.
The main obstacle is DNA degradation, such as cross-
linking between nucleic acid strands, DNA adducts with
histones or nucleic acid binding proteins, and breaking
and depurination of DNA. Recently, a one-step chemical
labeling method, called the Universal Linkage System
(ULS), has been put into production. This method yields
precise, robust and high-quality aCGH data by labeling
DNA with fluorescent dyes at the N7 position of gua-
nine without enzymatic reaction, which is subject to
perturbation by degraded DNA [18-20].
In the present study, we analyzed FFPE archival breast
cancer tissues from A-bomb survivors by aCGH using a
high density oligonucleotide microarray and ULS label-
ing to determine the effect of A-bomb radiation on
genomic alterations during breast carcinogenesis. This
study revealed a higher incidence of CNA in breast can-
cer tissue from A-bomb survivors than in tissue from
calendar year-matched control patients, suggesting a
role for GIN during breast carcinogenesis in A-bomb
survivors. To the best of our knowledge, this is the first
report of an aCGH analysis with solid tumors from A-
bomb survivors.
Methods
Tumor samples and clinical information
All samples were FFPE tissues. An A-bomb survivor was
defined in the present study as a person who received
the “Atomic Bomb Survivor’sH e a l t hH a n d b o o k ” pro-
duced by Nagasaki city authorities since the establish-
ment of the Atomic Bomb Survivors’ Medical
Treatment Law in April 1957. Our previous report has
already identified 35 breast cancers from A-bomb survi-
vors exposed at or less than 1.5 km from the hypocenter
in pathological records collected from 1961 to 1999 at
the Nagasaki University Hospital [15]. The estimated
doses in Nagasaki survivors who were not shielded at
the time of explosion were 924.7 centigrays (cGy) at 1
km and 120.7 cGy at 1.5 km from the hypocenter [21].
Simultaneously, we have already analyzed HER2 and C-
MYC gene amplification by FISH method with FFPE
samples and revealed that 26 out of 35 cases show clear
hybridization signals for HER2 and/or C-MYC gene
amplification. In this study, 15 (mean age: 58.0 years,
range: 45.4-82.8 years) out of 26 cases are available for
aCGH analysis because there is a limit to the amount of
tissues. As control subjects, 13 cases of invasive ductal
carcinoma from calendar year-matched patients
(matched on date of both diagnosis and birth; mean age:
55.5 years, range: 43.0-69.1 years), who did not receive
“Health Handbook” according to the Atomic Bomb Sur-
vivors’ Medical Treatment Law, were also analyzed. All
clinicopathologic information including exposure dis-
tance, diagnosis, the modified Bloom-Richardson histo-
logic grading, had been determined in our previous
study [15]. Clinicopathological findings of these samples
are provided in Additional file 1, Table S1. All experi-
mental procedures for this study were approved by
Committee for the Ethical Issues on Human Genome
and Gene Analysis at Nagasaki University (Protocol No.
0305150036-2).
DNA extraction
Tumor DNA was extracted from FFPE archival tissues,
as reported previously [22]. Briefly, using ten 10 μm-
thick sections, tumor areas containing more than 70%
tumor cells, identified by a guide slide stained with
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FFPE block. Paraffin removal was performed in 80%
xylene and tissues were washed twice with absolute
ethanol, and deparaffinized tissue pieces were spun
down. After drying, pellets were resuspended in 360 μL
of buffer ATL (QIAmp DNA Mini Kit, Quiagen, Ger-
many) and incubated at 95°C for 15 minutes, followed
by cooling to room temperature. Samples were immedi-
ately digested with proteinase K for three days at 56°C
in a rotation oven with periodic mixing and addition of
fresh proteinase K every 24 hours. DNA was collected
using the QIAmp DNA Mini Kit according to the man-
ufacturer’s instructions. Specifically, 400 μL of buffer AL
(equal volume to sample suspension) was added to the
sample and incubated at 70°C for 10 minutes. 400 μLo f
absolute ethanol was then added. The sample solution
was then placed into the spin column and centrifuged
for 1 minute at 8000 × g. The spin column was washed
twice with 500 μL of buffer AW1 by centrifugation at
8000 × g for one minute and then washed with buffer
AW2 by centrifugation at 14,000 × g for three minutes.
The DNA was finally eluted with 55 μLb u f f e rA E .
Extracted DNA was quantified on a NanoDrop ND-
1000 spectrophotometer (NanoDrop Technologies, Wil-
mington, DE, USA).
aCGH analysis
The Genomic DNA ULS Labeling Kit (Agilent technolo-
gies, USA) was used to chemically label 500 ng of tumor
DNA from samples and from reference female genomic
DNA (Promega, USA) with Cy5 or Cy3 dye for 30 min-
utes at 85°C, respectively, followed by purification using
Agilent-KREApure™ columns. Because ULS method
labeled DNA with fluorescent dyes directly without any
amplification steps or enzymatic reaction, this method is
suitable for aCGH analysis using degraded DNA such as
from FFPE blocks [18-20]. Dye-flip analyses were con-
ducted on 6 of 28 samples, where samples were labeled
with Cy3 and references were labeled with Cy5. Purified,
labeled samples were then combined and mixed with
human Cot-1 DNA (Invitrogen, USA), Agilent 10×
Blocking Agent and Agilent 2× Hybridization Solution.
Prior to array hybridization, hybridization mixtures were
denatured at 95°C for 3 minutes and incubated at 37°C
for 30 minutes. Agilent CGHblock was added and sam-
ples were hybridized to the SurePrint G3 Human CGH 8
× 60 K Microarray, which contains 8 identical arrays con-
sisting of ~63,000 in situ synthesized 60-mer oligonu-
cleotide probes that span coding and noncoding
sequences with an average spatial resolution of ~54 kb.
Hybridization was carried out at 65°C for 40 hours before
washing in Agilent Oligo aCGH Wash Buffer 1 at room
temperature for 5 minutes, followed by washing in Agi-
lent Oligo aCGH Wash Buffer 2 at 37°C for 1 minute.
Scanning and image analysis were done on an Agilent
DNA Microarray Scanner. Feature Extraction Software
(version 9.5) was used for data extraction from raw
microarray image files. Agilent Genomic Workbench
(version 5.0) was used to visualize, detect and analyze
chromosomal patterns using an ADM-2 algorithm with
the threshold set to 5.5. A copy number gain was
defined as a log 2 ratio > 0.25 and a copy number loss
was defined as a log 2 ratio < -0.25.
Statistical analysis
The total length of the CNA, which is the sum of each
segment gained or lost, was used as an indicator of
GIN. To determine the effect of each clinicopathological
factor on the natural logarithm of GIN, Student’s
(Welch’s) t-test or analysis of variance and the signifi-
cance test of Pearson’s correlation coefficient were per-
formed. Means and proportions of each
clinicopathological factor were compared between A-
bomb survivors and control using t-tests, Fishers exact
tests and Cochran-Armitage tests. We evaluated the
impact of A-bomb exposure, age at the time of diagno-
sis, storage time, histological grade according to the
modified Bloom-Richardson histologic grading system
[23], derivative log ratio spread (DLRSpread), which esti-
mates the log ratio noise by calculating the spread of log
ratio differences between consecutive probes along all
chromosomes, HER2 amplification and C-MYC amplifi-
cation determined by FISH on GIN using analysis of
covariance which is a technique that combines the fea-
t u r e so fa n a l y s i so fv a r i a n c ea n dr e g r e s s i o n .O u rm o d e l
was
Yij = μi +
6 
k=1
βk(Xkij − ¯ Xk..)+εij
where Yij is the natural logarithm of GIN of the jth
o b s e r v a t i o ni nt h eith class and μi represents the popu-
lation means of the A-bomb exposure classes, bk is the
regression coefficient of Y on Xk, εij is the residual.
Here, Xk is the variable which represents age at the time
of diagnosis, DLRSpread, HER2 amplification, C-MYC
amplification, histological grade and storage time.
Effects were considered statistically significant when
P-values were less than 0.05. The CORR, TTEST, FREQ
and GLM procedures in the SAS system (version 9.1.3)
was utilized for calculation.
Results
Results of aCGH analysis
The mean of the DLRSpread was 0.54 (range, 0.26 to
1.05) (Additional file 1, Table S1). As a quality assess-
ment measure, we examined the concordance of the
dye-flip analysis and the correlation between aCGH and
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amplification. In the 6 samples with dye-flip analyses,
the mean of the concordance rate of each paired sample
was 76.0% (range, 43.2% to 96.1%) (Additional file 2,
Table S2). The concordance rate of each paired sample
was defined as the ratio of length of copy number aber-
rant region in one dye combination to the dye-flipped
combination in each sample. To confirm the validity of
aCGH results using FFPE samples, we compared the
results of amplification status of HER2 and C-MYC in
the aCGH and FISH results. HER2 was amplified in 9 of
25 samples, in which showed clear hybridization signals
in the FISH analysis. In 7 of these 9 samples, the log 2
ratio for the probe sets (A_14_P121276, A_14_P114826
and triplicate of A_16_P20643178) corresponding to the
HER-2 gene was > 0.25, which met our criteria for a
gain based on aCGH results. The sensitivity, specificity
and overall accuracy for the HER2 gene were 77.8%,
93.8% and 88%, respectively (Additional file 3, Figure
S1). Whereas C-MYC was amplified in 11 of 23 samples,
in which showed clear hybridization signals in the FISH
analysis, only two of these 11 samples showed a gain for
the probe sets (A_14_P128991, A_14_P138867 and
A_14_P137636) corresponding to the C-MYC gene
based on aCGH results. The sensitivity, specificity and
overall accuracy for the C-MYC gene were 18%, 75%
and 48%, respectively (Additional file 4, Figure S2).
In our detection setting, the ADM-2 algorithm with the
threshold set to 5.5, CNA were detected in all samples.
The mean of the total number of site and the length of
CNA were 10.29 (range, 1 to 28) and 105,400,874 bp
(range, 607,921 bp to 525,839,497), respectively (Addi-
tional file 1, Table S1), and these values varied from case
to case (Additional file 5, Figure S3).
Correlation between GIN and clinicopathological findings
The results of comparisons of clinicopathological pro-
files of breast cancer between A-bomb survivors and
control are shown in Table 1. Proportions of histological
grade and the incidence of HER2 amplification were sig-
nificantly higher in A-bomb survivors than in controls
(P = 0.04, P = 0.04, respectively), which is consistent
with our data published previously [15]. The total length
and number of CNA tended to be larger in the A-bomb
survivors (P = 0.15, P = 0.16, respectively).
The correlations between the total length of CNA and
histological subtypes, histological grade, status of axillary
lymph node metastasis, status of estrogen receptor (ER),
HER2/C-MYC amplifications determined by FISH, age
at the time of diagnosis, tumor size, age of samples,
DLRSpread, age of the time at the A-bomb exposure,
the exposure distance from the hypocenter and time
between age at diagnosis and age at exposure were
tested (Table 2, Table 3). Among these factors,
DLRSpread was negatively correlated with the total
length of CNA significantly (P = 0.034, r = -0.40) and
age at the time of diagnosis, age of samples tended to
be correlated with that negatively (P = 0.055, r = -0.37)
and positively (P = 0.064, r = 0.35), respectively. Nota-
bly, among A-bomb survivors, latent period from irra-
diation was inversely correlated with the total length of
CNA, indicating an involvement of GIN in the case of
breast cancer which showed early onset from an initia-
tion event by A-bomb exposure.
The multivariate analysis using analysis of covariance
revealed that the status of A-bomb exposure was the
most significant factor for the total length of CNA even
excluding the effect of HER2 and C-MYC amplification,
histological grade, age at the time of diagnosis, age of
samples and DLRSpread (Figure 1, Table 4). Analysis of
covariance-adjusted difference in means between the A-
bomb exposed group and the unexposed group is
63,151,697 (95%CI, 18,291,298 to 151,682,068; P =
0.005) for GIN.
Discussion
Ionizing radiation is an established risk factor for breast
cancers [24-27]. Several epidemiologic reports have sug-
gested that an increased risk of cancer has continued for
decades after exposure, and that a higher risk of certain
types of cancers still persists in A-bomb survivors
[9-14]. Thus, a long-lasting health effect is considered to
be a contributing factor in tumorigenesis in A-bomb
survivors. We have recently demonstrated an association
of oncogene amplification in breast cancers among A-
bomb survivors with radiation exposure [15], which can
be regarded as being the results of positive selection
during breast carcinogenesis. This finding suggests that
A-bomb radiation may affect the development of onco-
gene amplification by inducing a higher level of GIN in
breast cancers found in survivors. The current study
was carried out to further confirm the enhanced GIN in
A-bomb radiation-associated breast cancers using the
aCGH method. The aCGH method is a quite useful
technique to detect the DNA CNA as an indicator of
GIN, which represents chromosomal loss and gain
caused by radiation-induced DNA double-strand breaks
[16]. Unger et al. [28] found DNA CNA pattern which
is characteristic of radiation-induced papillary thyroid
cancer in residents living in the vicinity of Chernobyl
using the aCGH method.
Tissue samples from A-bomb survivors are considered
to be extremely valuable biological materials with which
to analyze the radiation signature or radiation-associated
human health effects, particularly in low-dose and late
exposures. The molecular analyses of carcinogenesis in
A-bomb survivors require clinical data of individuals
and biological materials with pathologic data of tumors.
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bases: a clinical database providing exposure distance on
Nagasaki survivors registered at our institute which was
established in 1972 and a pathological database by the
Nagasaki Tumor Tissue Registry (NTTR) which was
established in 1974, allow us to obtain FFPE archival tis-
sue samples resected from A-bomb survivors. For the
genomic analyses, we confirmed the utility of FFPE
archival tissue with FISH methods to detect gene ampli-
fication despite DNA degradation caused by fixation and
long storage. In the present study, we conducted an
aCGH analysis using tumor DNA extracted from FFPE
archival breast cancer samples from A-bomb survivors.
To our knowledge, this is the first attempt to perform
an aCGH analysis with solid tumors from A-bomb sur-
vivors. The samples used in this study were very old,
with ranges 14 to 43 years (with a mean of 25 years) in
storage. The DLRSpread obtained was 0.26 to 1.05, with
a mean of 0.54, which indicated the relatively lower
quality of this experiment compared with that expected
with DNA from fresh frozen tissue or peripheral blood
lymphocyte. However, the status of HER2 oncogene
amplification based on aCGH result was highly concor-
dant with the results of FISH that the sensitivity, specifi-
city and accuracy were 77.8%, 93.8% and 88%,
respectively, which were comparable to the results from
former aCGH studies with FFPE archival tissue [29,30].
By contrast, the concordance was low for the status of
C-MYC oncogene amplification between the results
from aCGH and FISH, with the sensitivity, specificity
and accuracy being 18%, 75% and 48%, respectively.
This discordance, especially in sensitivity, may result
from the use of only three probes on the C-MYC gene
and a smaller change in amplification at the region
including C-MYC than the HER2 gene. Our results sug-
gest that the 60K×8 CGH array is a reliable technology
Table 1 Comparisons of clinicopathological factors of breast cancers between A-bomb survivor and control.
Clinicopathological profile A-bomb survivors (n = 15) Control (n = 13) P-value
Mean age of onset (years old) 58.0 (52.6, 63.4)
† 55.5 (49.7, 61.4) 0.51
1)
Mean tumor size (cm) 24.7 (20.7, 28.8) 36.2 (20.2, 52.3) 0.15
1)
Histological subtype
Papillo-tubular 9 4 0.29
2)
Solid-tubular 1 2
Scirrhous 5 7
Histological grade
I 1 3 0.04
3)
II 5 7
III 9 3
Lymph node metastasis
Positive 8 5 0.60
4)
Negative 4 4
Unknown 3 4
ER status
Positive 7 8 0.26
4)
Negative 8 5
PgR status
Positive 7 8 0.43
4)
Negative 8 5
HER2 amplification (FISH)
Positive 7 2 0.04
4)
Negative 5 11
No signal 3 0
C-MYC amplification (FISH)
Positive 9 2 0.09
4)
Negative 5 7
No signal 1 4
Mean total length of CNA (bp) 64,032,415
(29,443,979, 139,238,660)
23,924,175
(6,936,445, 82,515,771)
0.15
1)
Mean number of CNA 12.2 (8.4, 16.0) 8.08 (3.0, 13.1) 0.16
1)
†: 95% confidence interval, CNA: copy number aberrations
1): t-test, 2): c
2-test, 3): Cochran-Armitage test, 4): Fisher’s exact test
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changes.
Our aCGH analysis showed a great deal of variety in
its amount and pattern of genomic alterations from case
to case. In comparison with previous reports on breast
cancers from general population, mean number of CNA
in our cases seemed to be relatively small (mean: 12.2,
range: 2-28) but recurrently affected regions (8q24.3,
17q12, 19p13.11, 1q21.2-q22: Additional file 5, Figure
S3) found in our cases were concordant [4,7,31-33].
However, direct comparisons of the current results with
published results in aCGH are practically difficult
because the results of aCGH analyses are greatly influ-
enced by the array design and type of samples (e.g.,
fresh frozen or FFPE). A previous study of an aCGH
analysis of radiation-induced and spontaneous rat mam-
mary carcinoma indicated that the frequency of carci-
noma having any CNA and the number of CNA in
radiation-induced carcinoma were significantly greater
than that observed in the spontaneous carcinoma [34].
Another study of an aCGH analysis of premenopausal
breast cancers in the residents from a nuclear fallout-
contaminated area in Belarus did not show any signifi-
cant differences or tendencies in the average number of
Table 2 Comparisons of total length of copy number aberrations (CNA) by clinicopathological factor of breast cancers.
Clinicopathological factor Total (N = 28)
n (%)
Mean total length of
CNA (bp)
P-value
Histological subtype
Papillo-tubular 13 (46) 27,487,678 0.54
1)
Solid-tubular 3 (11) 41,158,092
Scirrhous 12 (43) 61,520,542
Histological grade
I 4 (14) 49,011,523 0.32
2)
II 12 (43) 47,158,730
III 12 (43) 32,711,871
Axillary lymph node metastasis
Positive 13 (62) 30,993,870 0.30
3)
Negative 8 (38) 59,602,019
ER status
Positive 14 (50) 53,249,555 0.43
3)
Negative 14 (50) 30,863,969
HER2 amplification (FISH)
Positive 9 (36) 28,970,829 0.75
3)
Negative 16 (64) 37,017,451
C-MYC amplification (FISH)
Positive 11 (48) 38,698,059 0.46
3)
Negative 12 (52) 22,102,472
1): analysis of variance, 2): Jonckheere-Terpstra trend test, 3): t-test
Table 3 Correlation analyses between clinicopathological factors and total length of copy number aberrations in
breast cancers.
Mean total length of
copy number aberrations (bp)
Clinical factors All cases
(n = 28)
A-bomb survivors (n = 15)
r* P-value* r* P-value*
Age at the time of diagnosis -0.37 0.055 -0.59 0.021
Tumor size (cm) 0.042 0.83 -0.25 0.37
Storage time (years) 0.35 0.064 0.49 0.067
DLRSpread -0.40 0.034 -0.38 0.16
Age of the time of exposure to the A-bomb** -0.31 0.25
Exposure distance from the hypocenter (km)** 0.11 0.70
Time between age at diagnosis and exposure (year)** -0.52 0.047
*Pearson’s correlation coefficient. **Only among A-bomb survivors
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from Western New York, even though breast cancer
from Belarus had significant l ym o r ea v e r a g en u m b e ro f
gains [35]. These discrepancies may result from differ-
ences in the experimental models, since the former is a
study of a simplified animal cancer model and the latter
is an observational study of human cancer affected by
many etiological factors. But the present study endorsed
the former result with a tendency for breast cancer in
A-bomb survivors to have a higher number of CNA (P
= 0.16, Table 1, Additional file 1, Table S1). Further-
more, mean total length of CNA were also larger, if not
Total length of copy number  
aberrations (log Mb) 
A-bomb survivors (n= 15) 
Control patients    (n= 13) 
Figure 1 Relationship between genomic instability and affecting clinical factors. Blue and green plots indicate atomic bomb survivors and
control patients, respectively. Blue and Green plane represent regression plane of each group. X-axis; years of sample storage time. Y-axis;
derivative log ratio spread (DLRSpread). Z-axis; natural logarithm of total number of copy number aberrations.
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group (P = 0.15, Table 1, Additional file 1, Table S1).
Herein, we assumed the total length of CNA as an indi-
cator of GIN because the amount of CNA represents
the consequences of double-strand breaks, abnormal
DNA damage repairs and gross rearrangements of chro-
mosomes [1,16], and a consecutive changes of probes is
considered to be much more important than a change
of only one probe in such experimental model using
high density probes and relatively noisy data. Since high
histological grade, ER negative expression, early age of
onset and HER2 amplification were reported to be cor-
related with higher incidence of genomic aberrations
[4], we examined the correlation between the total
length of CNA and clinicopathological factors, followed
by multivariate analysis using analysis of covariance to
evaluate the impact (effect) of A-bomb exposure, age at
the time of diagnosis, HER2 and C-MYC amplification,
histological grade, storage time, and DLRSpread on
GIN, which have shown that the status of A-bomb
exposure showed a significant correlation after the
exclusion of confounding factor by the multivariate ana-
lysis (Table 4). Thus, we have demonstrated that breast
cancers in A-bomb survivors harbored significant GIN
independently of the effect of other clinicopathological
factors.
Conclusions
The present study indicated that archival FFPE tissues
from A-bomb survivors are useful for genome-wide
aCGH analysis and A-bomb radiation exposure induced
GIN not only at the region of the HER2 and C-MYC
oncogenes but throughout the whole genome in breast
cancers by aCGH. The crucial mechanisms that can
account for the continuously higher incidence of breast
cancers in A-bomb survivors for decades remain to be
determined. Further research on the molecular mechan-
isms to induce a long-lasting GIN in the breast tissue
from survivors can contribute to an understanding of
radiation-associated carcinogenesis.
Additional material
Additional file 1: Table S1. Summary of clinicopathological factors
and aCGH Analysis.
Additional file 2: Table S2. Result of dye-flip analysis.
Additional file 3: Figure S1. Chromosomal view of chromosome 17
and comparison of the results from FISH and aCGH analyses on
HER2 oncogene. Log2 ratio values for all oligonucleotide probes are
plotted as a function of their chromosomal position. Each point
represents a single probe and the blue vertical line indicates the position
of the HER2 oncogene. Aberration calls identified by ADM-2 algorithm
are shown.
Additional file 4: Figure S2. Chromosomal view of chromosome 8
and comparison of the results from FISH and aCGH analyses on C-
MYC ongcogene. Log2 ratio values for all oligonucleotide probes are
plotted as a function of their chromosomal position. Each point
represents a single probe and the blue vertical line indicates the position
of the C-MYC oncogene. Aberration calls identified by ADM-2 algorithm
are shown.
Additional file 5: Figure S3. Graphic display of whole genomic
aberrations in atomic bomb survivors (upper panel) and control
patients (lower panel). The panels to the right of each chromosome
shows the frequency of gains, indicated by the red bars ranging from
0% to 100%, and losses, indicated by the green bars ranging from 0% to
100%.
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